Effects of Oxaliplatin-Induced Peripheral Neuropathy on Hand Function, Grip Strength and Quality of Life in Colorectal Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

84 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-24

Study Completion Date

2026-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the effects of oxaliplatin-induced peripheral neuropathy on hand function, grip strength, and quality of life in colorectal cancer patients. Assessing the motor symptoms of CIPN and sharing the results in clinical settings will help guide evidence-based practices and interventions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Term Effect of Oxaliplatin Treatment in Cancer Survivors

NCT02970526

Colorectal Cancer Survivors Oxaliplatin Regimen Adult

COMPLETED

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

NCT04034355

Colorectal Cancer Chemotherapy-induced Peripheral Neuropathy

TERMINATED PHASE3

Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients

NCT06873360

Peripheral Neuropathy Due to Chemotherapy

RECRUITING

Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer

NCT02428101

Gastrointestinal Tract Cancer Peripheral Neuropathy

ENROLLING_BY_INVITATION

Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients

NCT05510856

Oncology

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oxaliplatin is a chemotherapy drug frequently used in the treatment of colorectal cancers, the third most common type of cancer. However, oxaliplatin is associated with long-term neurotoxicity, the most common dose-limiting side effect. Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of platinum-based chemotherapy agents, such as oxaliplatin. CIPN limits patients' ability to tolerate treatment and adversely affects long-term quality of life and physical functionality. In individuals undergoing colorectal cancer treatment, the prevalence of CIPN has been reported as 58% at 6 months, 45% at 12 months, 32% at 24 months, and 24% at 36 months post-treatment. Additionally, oxaliplatin exhibits a "coasting phenomenon," in which CIPN symptoms continue to worsen for approximately 3 months after treatment. Although the incidence and sensory symptoms of oxaliplatin-induced CIPN during chemotherapy have been well documented, the chronic-phase motor symptom burden of oxaliplatin-induced CIPN has not been reported. Studies investigating the motor aspects of CIPN are insufficient, and further research is needed to determine its prevalence, progression, and impact on functional outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Neuropathy Due to Chemotherapy Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients Hand Strength

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observational only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Receiving chemotherapy due to a diagnosis of locally advanced or metastatic colorectal cancer,
* Having received at least 3 cycles of single or combined oxaliplatin-based chemotherapy,
* Aged 20 years or older,
* No speech or hearing impairments,
* Voluntary participation in the study.

Exclusion Criteria

* Development of peripheral neuropathy due to causes other than chemotherapy (e.g., tumor compression, nutritional disorders, infections, or major systemic diseases such as diabetes mellitus),
* Presence of mental or cooperation problems.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No